The FDA Warned 30 Telehealth Companies and Big Pharma Smiled
The FDA sent warning letters to 30 telehealth firms over compounded GLP-1 marketing while Novo Nordisk sued Hims -- consumer safety or corporate protectionism?
Nora Whitfield
Bureau: Chicago
Stopping Ozempic Raises Cardiovascular Risk by 22 Percent
A major study found that patients who stopped GLP-1 drugs for two years faced a 22 percent increase in heart attack, stroke, and death risk.
The Wegovy Pill Has 400,000 Americans and Weight Loss Will Never Be the Same
Oral Wegovy reached 400,000 American users within ten weeks of FDA approval, making it the fastest-adopted obesity drug in history.
GLP-1 Drugs May Also Reduce Substance Use Disorders
A study of 600,000 veterans found GLP-1 drugs reduced alcohol use disorder risk by 18 percent, opioid risk by 25 percent, and cocaine risk by 20 percent.
GLP-1 Drugs Are Reshaping Society Far Beyond Medicine: Dating, Insurance, Fashion, Food
GLP-1 weight-loss drugs are now transforming dating culture, insurance markets, fashion, and the food industry as adoption reaches 1 in 8 US adults.